New trends in the development of cancer vaccines

In Vivo

Volumn 12, Issue 6, 1998, Pages 629-638

  Minev, Boris R ^a   Chavez, Frances L ^a   Mitchell, Malcolm S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antigen presentation; Cancer vaccines; Immunotherapy; Recombinant vaccines; Signal sequence; Synthetic peptides

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; MELANOMA ANTIGEN; RECOMBINANT VACCINE; TUMOR ANTIGEN;

CANCER; CANCER IMMUNIZATION; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN; RECOMBINANT DNA TECHNOLOGY; REVIEW; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 0032408384     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Germain RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76: 287-299, 1994.
2. Rammensee HG, Friede T and Stevanoviic S: MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228, 1995.
3. Rammensee HG: Antigen presentation-recent developments. Int. Arch Allergy Immunol 110: 299-307, 1996.
4. Yewdell JW and Bennink JR: Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol 52: 1-123, 1992.
5. Spies T, Cerundolo V, Colonna M, Cresswell P, Townsend A and DeMars R: Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature 355: 644-646, 1992.
6. Heemels MT and Ploegh H: Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem 64: 463-491, 1995.
7. Lehner PJ and Cresswell P: Processing and delivery of peptides presented by MHC class I molecules. Curr Opin Immunol 8: 59-67, 1996.
8. Liu CC, Young LH and Young JD: Lymphocyte-mediated cytolysis and disease. N Engl J Med 335: 1651-1659, 1996.
9. Aichele P, Hengartner H, Zinkernagel RM and Schulz M: Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med 171: 1815-1820, 1990.
10. Schulz M, Zinkernagel RM and Hengartner H: Peptide-induced antiviral protection by cytotoxic T cells. Proc Natl Acad Sci U.S.A. 88: 991-993, 1991.
11. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA and Marincola FM: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 3: 37-44, 1997.
12. Lipford GB, Hoffman M, Wagner H and Heeg K: Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J Immunol 150: 1212-1222, 1993.
13. Zhou F, BT Huang Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. Cancer Res 52: 6287-6291, 1992.
14. Harty JT and Bevan MJ: CDS+ T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo. J Exp Med 175: 1531-1538, 1992.
15. Deres K, Schild H, Wiesmüller K-H, Jung G and Rammensee H-G: In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342: 561-564, 1989.
16. Noguchi Y, Chen YT and Old LJ: A mouse mutant p53 product recognized by CD4+ and CDS+ T cells. Proc Natl Acad Sci U.S.A. 97: 3171-3175, 1994.
17. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E and DeLeo AB: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183: 1357-1365, 1996.
18. Minev BR, McFarland BJ, Spiess PJ, Rosenberg SA and Restifo NP: Insertion signal sequence fused to minimal peptides elicits specific CDS+ T-cell responses and prolongs survival of thymomabearing mice. Cancer Res 54: 4155-4161, 1994.
19. Kawakami Y, Robbins PF and Rosenberg SA: Human melanoma antigens recognized by T lymphocytes. Keio J Med 45: 100-108, 1996.
20. Maeurer MJ, Storkus WJ, Kirkwood JM and Lotze MT: New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 6: 11-24, 1996.
21. Disis ML, Smith JW, Murphy AE, Chen W and Cheever MA: In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54: 1071-1076, 1994.
22. Fisk B, Blevins TL, Wharton JT and Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109-2117, 1995.
23. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J and Burchell J: A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263: 12820-12823, 1988.
24. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R and Humblet Y: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63: 883-885, 1995.
25. Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y and Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 55: 4972-4979, 1995.
26. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SK, Ergin MT, Ozols J and Meehan J: Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci U.S.A. 92: 8078-8082, 1995.
27. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT and Mukherji B: Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 50: 2479-2483, 1996.
28. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M and Knuth A: Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanomaassociated antigens. Int J Cancer 66: 162-169, 1996.
29. Jager E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D, Ilsemann C, Hagedorn M, Oesch F, and Knuth A: Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67: 54-62, 1996.
30. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Gedde-Dahl Stokke, KT Solheim, BG Egge, TS Soreide, O Thorsby E and Gaudernack G: Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 65: 450-453, 1996.
31. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, Sette A and Serra HM: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U.S.A. 91: 2105-2109, 1994.
32. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Furze J and Bartholomeuz R: Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95: 341-349, 1995.
33. Sette A, Alexander J, Ruppert J, Snoke K, Franco A, Ishioka G, and Grey HM: Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu Rev Immunol 12: 413-431, 1994.
34. Chen YT, Stocken E, Chen Y, Garin-Chesa P, Rettig WJ, van der Bruggen P, Boon T, and Old LJ: Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci U.S.A. 91: 1004-1008, 1994.
35. Lipford GB, Bauer S, Wagner H and Heeg K: Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6. Immunology 84: 298-303, 1995.
36. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA and Kawakami Y: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A *0201-binding residues. J Immunol 757: 2539-2548, 1996.
37. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley. ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH and White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine 4: 321-327, 1998.
38. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY and Schlom J: Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57: 4570-4577, 1997.
39. Minev BR, Chavez F and Mitchell MS: Synthetic fusion peptides improve Class I presentation of human melanoma antigen. Proceedings of the American Association for Cancer Research Annual Meeting 37: 477, 1996.
40. Rapoport TA: Transport of proteins across the. endoplasmic reticulum membrane. Science 258: 931-936, 1992.
41. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E and Engelhard VH: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255: 1261-1263, 1992.
42. Anderson K, Cresswell P, Gammon M, Hermes J, Williamson A, and Zweerink H: Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J Exp Med 174: 489-492, 1991.
43. Voigt S, Jungnickel B, Hartmann E and Rapoport TA:-Signal sequence-dependent function of the TRAM protein during early phases of protein transport across the endoplasmic reticulum membrane. J Cell Biol 134: 25-35, 1996.
44. Okada CY and Rechsteiner M: Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles. Cell 29: 33-41, 1982.
45. Moore MW, Carbone FR and Bevan MJ: Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777-785, 1988.
46. Persson H, Jornvall H and Zabielski J: Multiple mRNA species for the precursor to an adenovirus-encoded glycoprotein: identification and structure of the signal sequence. Proc Natl Acad Sci U.S.A. 77: 6349-6353, 1980.
47. Houghton M, Stewart AG, Doel SM, Emtage JS, Eaton MA, Smith JC, Patel TP, Lewis HM, Porter AG, Birch JR; Cartwright T and Carey NH: The amino-terminal sequence of human fibroblast interferon as deduced from reverse transcripts obtained using synthetic oligonucleotide primers. Nucleic Acids Res 8: 1913-1931, 1980.
48. Chavez FL, Minev BR and Mitchell MS: Improving the presentation of a human melanoma antigen by synthetic peptide modifications. J Investigative Medicine 44: 136A, 1996.
49. Wiedmann M, Kurzchalia TV, Hartmann E and Rapoport TA: A signal sequence receptor in the endoplasmic reticulum membrane. Nature 328: 830-833, 1987.
50. Celis E, Sette A and Grey HM: Epitope selection and development of peptide based vaccines to treat cancer. Semin Cancer Biol 6: 329-336, 1995.
51. Moss B: Vaccinia virus: a tool for research and vaccine development. Science 252: 1662-1667, 1991.
52. Restifo NP, Minev BR, Taggarse AS, McFarland BJ, Wang M, and Irvine KR: Enhancing the recognition of tumour associated antigens. Folia Biol (Praha) 40: 74-88, 1994.
53. Irvine KR, McCabe BJ, Rosenberg SA and Restifo NP: Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J Immunol 154: 4651-4657, 1995.
54. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, and Restifo NP: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immuhol 154: 5282-5292, 1995.
55. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D and Kantor JA: A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 63: 231-237, 1995.
56. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM and Schlom J: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87: 982-990, 1995.
57. McCabe BJ, Irvine KR, Nishimura MI, Yang JC, Spiess PJ, Shulman EP, Rosenberg SA and Restifo NP: Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res 55: 1741-1747, 1995.
58. Restifo NP, Bacik I, Irvine KR, Yewdell JW, McCabe BJ, Anderson RW, Eisenlohr LC, Rosenberg SA and Bennink JR: Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol 154: 4414-4422, 1995.
59. Bacik I, Cox JH, Anderson R, Yewdell JW and Bennink JR: TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino-but not carboxyl-terminus of the peptide. J Immunol 152: 381-387, 1994.
60. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT and Pardoll DM: Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U.S.A. 92: 11671-11675, 1995.
61. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, and Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26, 1996.
62. McElrath MJ, Corey L, Berger D, Huffman MC, Klucking S, Dragavon J, Peterson E and Greenberg PD: Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. J Infect Dis 169: 41-47, 1994.
63. Baxby D and Paoletti E: Potential use of non-replicating vectors as recombinant vaccines. Vaccine 10: 8-9, 1992.
64. Somogyi P, Frazier J and Skinner MA: Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology 197: 439-444, 1993.
65. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA and Restifo NP: Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumorassociated antigen. J Immunol 154: 4685-4692, 1995.
66. Taylor J, Weinberg R, Languet B, Desmettre P and Paoletti E: Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 6: 497-503, 1988.
67. Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, and Plotkin S: Immunisation with canarypox virus expressing rabies glycoprotein.. Lancet 339: 1429-1432, 1992.
68. Cox WI, Tartaglia J and Paoletti E: Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 195: 845-850, 1993.
69. Roth J, Dittmer D; Rea D, Tartaglia J, Paoletti E and Levine AJ: p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U.S.A. 93: 4781-4786, 1996.
70. Hodge JW, McLaughlin JP, Kantor JA, and Schlom J: Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15: 759-768, 1997.
71. Meyer H, Sutler G and Mayr A: Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J gen Virol 72: 1031-1038, 1991.
72. Sutter G and Moss B: Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U.S.A. 89: 10847-10851, 1992.
73. Sutter G, Wyatt LS, Foley PL, Bennink JR and Moss B: A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12: 1032-1040, 1994.
74. Wolff JA, Dowty ME, Jiao S, Repetto G, Berg RK, Ludtke JJ, Williams P and Slautterback DB: Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle. J Cell Sci 103: 1249-1259, 1992.
75. Wolff JA, Ludtke JJ, Acsadi G, Williams P and Jani A: Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1: 363-369, 1992.
76. Yankauckas MA, Morrow JE, Parker SE, Abai A, Rhodes GH, Dwarki VJ and Gromkowski SH: Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol 12: 771-776, 1993.
77. Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH and Haynes JR: Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13: 1427-1430, 1995.
78. Fuller DH and Haynes JR: A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine AIDS Res Hum Retroviruses 10: 1433-1441, 1994.
79. Irvine KR, Rao JB, Rosenberg SA and Restifo NP: Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156: 238-245, 1996.
80. Conry RM, Widera G, LoBuglio AF, Fuller JT, Moore SE, Barlow DL, Turner J, Yang NS and Curiel DT: Selected strategies to augment polynucleotide immunization. Gene Ther 3: 67-74, 1996.
81. Condon C, Watkins SC, Celluzzi CM, Thompson K and Falo LD: DNA-based immunization by vivo vivo transfection of dendritic cells. Nat Med 2: 1122-1128, 1996.
82. Ulmer JB, Deck RR, Dewitt CM, Donnhly JI and Liu MA: Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 89: 59-67, 1996.
83. Corr M, Lee DJ, Carson DA and Tighe H: Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 184: 1555-1560, 1996.
84. Syrengelas AD, Chen TT and Levy R: DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 2: 1038-1041, 1996.
85. Kurth R: Risk potential of the chromosomal insertion of foreign DNA. Ann N Y Acad Sci 772: 140-151, 1995.
86. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296, 1991.
87. Cumberbatch M, Gould SJ, Peters SW and Kimber I: MHC class II expression by Langerhans' cells and lymph node dendritic cells: possible evidence for maturation of Langerhans' cells following contact sensitization. Immunology 74: 414-419, 1991.
88. Sallusto F, Cella M, Danieli C and Lanzavecchia A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182: 389-400, 1995.
89. Nijman HW, Kleijmeer MJ, Ossevoort MA, Oorschot VM, Vierboom MP, van de Keur M, Kenemans P, Kast WM, Geuze HJ and Melief CJ: Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells. J Exp Med 182: 163-174, 1995.
90. Zhou X, Liu T, Franksson L, Lederer E, Ljunggren HG and Jondal M: Characterization of TAP-independent and brefeldin A-resistant presentation of Sendai virus antigen to CDS+ cytotoxic T lymphocytes. Scand J Immunol 42: 66-75, 1995.
91. Kiertscher SM and Roth MD: Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol 59: 208-218, 1996.
92. Porgador A and Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182: 255-260, 1995.
93. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT and Falo LD: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183: 283-287, 1996.
94. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM and DeLeo AB: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1: 1297-1302, 1995.
95. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ and Kast WM: Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 18: 86-94, 1995.
96. Eberl G, Widmann C and Corradin G: The functional half-life of H-2Kd-restricted T cell epitopes on living cells. Eur J Immunol 26: 1993-1999, 1996.
97. Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD and Lotze MT: Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 26: 1335-1341, 1996.
98. Paglia P, Chiodoni C, Rodolfo M and Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183: 317-322, 1996.
99. Boczkowski D, Nair SK, Snyder D, and Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184: 465-472, 1996.
100. Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA and Hwu P: Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 186: 1213-1221, 1997.
101. Wan Y, Bramson J, Carter R, Graham F and Gauldie J: Dendritic cells transduced with an adenoviral vector encoding a model tumorassociated antigen for tumor vaccination. Hum Gene Ther 8: 1355-1363, 1997.
102. Yang JC, Fraker DL, Thom AK, Pass HI and Rosenberg SA: Isolation perfusion with tumor necrosis factor-alpha, interferongamma, and hyperthermia in the treatment of localized and metastatic cancer. Recent Results Cancer Res 138: 161-166, 1995.
103. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, Pathak R, Raper SE and Wilson JM: Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3: 306-312, 1997.
104. Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R, Dubinett S, Glaspy J, McBride WH and Economou JS: A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4: 17-25, 1997.
105. Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, Marincola F, Rosenberg SA, Moss B and Restifo NP: Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U.S.A. 94: 3183-3188, 1997.
106. Tuting T, DeLeo AB, Lotze MT and Storkus WJ: Genetically modified bone marrow-derived dendritic cells expressing tumorassociated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 27: 2702-2707, 1997.
107. Minev BR, Chavez FL and Mitchell MS: Enhancing class I antigen presentation by human dendritic cells loaded with fusion peptides. Proceedings of the American Accociation for Cancer Research Annual Meeting, 39: 173, 1998.
108. Mehta-Damani A, Markowicz S and Engleman EG: Generation of antigen-specific CDS+ CTLs from naive precursors. J Immunol 153: 996-1003, 1994.
109. Takamizawa M, Fagnoni F, Mehta-Damani A, Rivas A and Engleman EG: Cellular and molecular basis of human gamma delta T cell activation. Role of accessory molecules in alloactivation. J Clin Invest 95: 296-303, 1995.
110. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG and Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52-58, 1996.
111. Kwak LW, Campbell MJ, Crezwinski DK, Hatr S, Miller RA and Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327: 1209-1215, 1992.
112. Reichardt V, Okada C, Benike C, Long G, Engleman E, Blume K, and Levy R: Idiotypic vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation. Blood 88: 4811996.
113. Kim CJ, Prevette T, Cormier J, Overwrjk W, Roden M, Restifo NP, Rosenberg SA and Marincola FM: Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J Immunother 20: 276-286, 1997.
114. Mortarini R, Anichini A, Di Nicola M, Siena S, Bregni M, Belli F, Molla A, Gianni AM and Parmiani G: Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 57: 5534-5541, 1997.
115. Bakker AB, Marland G, de Boer AJ, Huijbens RJ, Danen EH, Adema GJ and Figdor CG: Generation of antimelanoma cytotoxic T lymphocytes from hearfhy donors after presentation of melanomaassociated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 55: 5330-5334, 1995.
116. Storkus WJ, Mayordomo JI, Deleo A, Zitvogel L, Tjandrawan T and Lotze MT: Dendritic cells pulsed with tumor epitopes elicit potent anti-tumor CTI in vitro and in vivo. 589, 1995. (Abstract)
117. Nestle FO, Alijagic S, Gilliet M, Sun M, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine 4: 328-332, 1998.
118. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P and Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178: 489-495, 1993.
119. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T and Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U.S.A. 91: 3515-3519, 1994.
120. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T and Rosenberg SA: Identification of a human melanoma antigen recognized by tumorinfiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U.SA. 91: 6458-6462, 1994.
121. Wang RF, Robbins PF, Kawakami Y, Kang XQ, and Rosenberg SA: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181: 799-804, 1995.
122. Wang RF, Appella E, Kawakami Y, Kang X and Rosenberg SA: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184: 2207-2216, 1996.
123. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM and Lerner AB: Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9: 689-696, 1983.
124. Takahashi T, Chapman PB, Yang SY, Hara I, Vijayasaradhi S and Houghton AN: Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 154: 772-779, 1995.
125. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, and van der Bruggen P: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2: 167-175, 1995.
126. Van den Eynde B, Peelers O, De Backer O, Gaugler B, Lucas S and Boon T: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182: 689-698, 1995.
127. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankein T, Meyer zum Buschenfelde KH and Beach D: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284, 1995.
128. Robbins PF, el-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, and Rosenberg SA: A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183: 1185-1192, 1996.
129. Nowak MA, May RM, Phillips RE, Rowland-Jones S, Lalloo DG, McAdam S, Klenerman P, Koppe B, Sigmund K and Bangham CR: Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 375: 606-611, 1995.
130. Toes RE, Offringa R, Blom RJ, Melief CJ, and Kast WM: Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U.S.A. 93: 7855-7860, 1996.
131. Aichele P, Brduscha-Riem K, Zinkernagel RM, Hengartner H and Pircher H: T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 182: 261-266, 1995.
132. Webb S, Morris C and Sprent J: Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 63: 1249-1256 1990.
133. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A and Moudgil K: Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11: 729-766, 1993.
134. Benichou G, Fedoseyeva E, Olson CA, Geysen HM, McMillan M and Sercarz EE: Disruption of the determinant hierarchy on a self-MHC peptide: concomitant tolerance induction to the dominant determinant and priming to the cryptic self-determinant. Int Immunol 6: 131-138, 1994.
135. McElrath MJ: Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol 6: 375-385, 1995.
136. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U.S.A. 90: 3539-3543, 1993.
137. Biron CA and Gazzinelli RT: Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Curr Opin Immunol 7: 485-496, 1995.
138. Reid CD, Stackpoole A, Meager A and Tikerpae J: Interactions of tumor necrosis factor with granulocyte-macrophage colonystimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 149: 2681-2688, 1992.
139. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S and Cheever MA: Granulocyte-macrophage colonystimulating factor: an effective adjuvant for protein and peptidebased vaccines. Blood 88: 202-210, 1996.
140. Meko JB, Yim JH, Tsung K and Norton JA: High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res 55: 4765-4770, 1995.
141. Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, Rosenberg SA and Restifo NP: IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol 156: 3357-3365, 1996.
142. Hoon DS, Yuzuki D, Hayashida M and Morton DL: Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 154: 730-737, 1995.